{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T19:22:49Z","timestamp":1776453769085,"version":"3.51.2"},"reference-count":50,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Urol\u00f3gicas Espa\u00f1olas"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.acuro.2020.08.003","type":"journal-article","created":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T21:38:13Z","timestamp":1601588293000},"page":"93-102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Tratamientos actuales tras fracaso a BCG en c\u00e1ncer de vejiga no m\u00fasculo-invasivo"],"prefix":"10.1016","volume":"45","author":[{"given":"M.","family":"\u00c1lvarez-Maestro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Guerrero-Ramos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Rodr\u00edguez-Faba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.L.","family":"Dom\u00ednguez-Escrig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.M.","family":"Fern\u00e1ndez-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.acuro.2020.08.003_bib0255","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Gu\u00e9rin for non-muscle-invasive bladder cancer","volume":"56","author":"Malmstr\u00f6m","year":"2009","journal-title":"Eur Urol."},{"key":"10.1016\/j.acuro.2020.08.003_bib0260","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","article-title":"Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity","volume":"169","author":"B\u00f6hle","year":"2003","journal-title":"J Urol."},{"key":"10.1016\/j.acuro.2020.08.003_bib0265","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016","volume":"71","author":"Babjuk","year":"2017","journal-title":"Eur Urol."},{"key":"10.1016\/j.acuro.2020.08.003_bib0270","year":"2018","journal-title":"BCG-Unresponsive Nonmuscle Invasive Bladder Cancer: Developing Drugs and Biologics for Treatment"},{"key":"10.1016\/j.acuro.2020.08.003_bib0275","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1053\/j.seminoncol.2014.09.004","article-title":"Mechanism of Action of Immunotherapy","volume":"41","author":"Disis","year":"2014","journal-title":"Semin Oncol."},{"issue":"7457","key":"10.1016\/j.acuro.2020.08.003_bib0280","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature."},{"issue":"10031","key":"10.1016\/j.acuro.2020.08.003_bib0285","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet."},{"key":"10.1016\/j.acuro.2020.08.003_bib0290","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.3892\/or.2015.3933","article-title":"The prognostic significance of PD-L1 in bladder cancer","volume":"33","author":"Huang","year":"2015","journal-title":"Oncol Rep."},{"key":"10.1016\/j.acuro.2020.08.003_bib0295","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/cncr.22588","article-title":"PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression","volume":"109","author":"Inman","year":"2007","journal-title":"Cancer."},{"key":"10.1016\/j.acuro.2020.08.003_bib0300","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.eururo.2018.06.045","article-title":"Conventional and PD-L1-expressing Regulatory T Cells are enriched during BCG Therapy and may limit its Efficacy","volume":"74","author":"Chevalier","year":"2018","journal-title":"Eur Urol."},{"key":"10.1016\/j.acuro.2020.08.003_bib0305","doi-asserted-by":"crossref","first-page":"34066","DOI":"10.18632\/oncotarget.26122","article-title":"Enhanced expression of PD-L1 in non-muscle-invasive bladder cancer after treatment with Bacillus Calmette-Guerin","volume":"9","author":"Hashizume","year":"2018","journal-title":"Oncotarget."},{"key":"10.1016\/j.acuro.2020.08.003_bib0310","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0022-5347(05)67799-3","article-title":"Efficacy and safety of valrubicin for the treatment of bacillus Calmette\u2013Guerin refractory carcinoma in situ of the bladder","volume":"163","author":"Steinberg","year":"2000","journal-title":"J Urol."},{"key":"10.1016\/j.acuro.2020.08.003_bib0315","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/j.urolonc.2012.04.010","article-title":"Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Gu\u00e9rin","volume":"31","author":"Dinney","year":"2013","journal-title":"Urol Oncol."},{"issue":"Suppl 10","key":"10.1016\/j.acuro.2020.08.003_bib0320","first-page":"3","article-title":"Gemcitabine: Preclinical pharmacology and mechanisms of action","volume":"23","author":"Plunkett","year":"1996","journal-title":"Semin Oncol."},{"key":"10.1016\/j.acuro.2020.08.003_bib0325","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1002\/cncr.23848","article-title":"A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: A retrospective experience","volume":"113","author":"Dash","year":"2008","journal-title":"Cancer."},{"key":"10.1016\/j.acuro.2020.08.003_bib0330","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2002.02.066","article-title":"Phase 1 trial of intravesical gemcitabine in bacillus Calmette-Gu\u00e9rin-refractory transitional-cell carcinoma of the bladder","volume":"20","author":"Dalbagni","year":"2002","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.acuro.2020.08.003_bib0335","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1016\/j.juro.2013.04.120","article-title":"Intravesical gemcitabine for high risk, nonmuscle invasive bladder cancer after Bacillus Calmette-Gu\u00e9rin treatment failure","volume":"190","author":"Sternberg","year":"2013","journal-title":"J Urol."},{"key":"10.1016\/j.acuro.2020.08.003_bib0340","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.juro.2013.04.031","article-title":"SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Gu\u00e9rin","volume":"190","author":"Skinner","year":"2013","journal-title":"J Urol."},{"key":"10.1016\/j.acuro.2020.08.003_bib0345","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1200\/JCO.2005.03.1161","article-title":"Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy","volume":"24","author":"McKiernan","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acuro.2020.08.003_bib0350","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.juro.2012.10.068","article-title":"Long-Term Survival Outcomes with Intravesical Docetaxel for Recurrent Nonmuscle Invasive Bladder Cancer After Previous Bacillus Calmette-Guerin Therapy","volume":"189","author":"Barlow","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.acuro.2020.08.003_bib0355","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0959-8049(98)00030-6","article-title":"A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum Italian co-operative group on bladder cancer","volume":"34","author":"Lorusso","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.acuro.2020.08.003_bib0360","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1200\/JCO.1997.15.11.3394","article-title":"Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer","volume":"15","author":"Stadler","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acuro.2020.08.003_bib0365","author":"Brooks","year":"2020","journal-title":"A multi-institutional evaluation of rescue therapy with intravesical gemcitabine and docetaxel for non-muscle invasive bladder cancer after BCG failure"},{"key":"10.1016\/j.acuro.2020.08.003_bib0370","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.1097\/JU.0000000000000846.07","article-title":"A phase 3 study to evaluate the safety and efficacy of intravesical nadofaragene firadenovec for patients with high-grade BCG unresponsive non-muscle invasive bladder cancer: papillary disease cohort results","volume":"203","author":"Boorjan","year":"2020","journal-title":"J Urol."},{"key":"10.1016\/j.acuro.2020.08.003_bib0375","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1046\/j.0306-5251.2001.01449.x","article-title":"Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma","volume":"52","author":"Paroni","year":"2001","journal-title":"Br J Clin Pharmacol."},{"key":"10.1016\/j.acuro.2020.08.003_bib0380","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3109\/02656738809029305","article-title":"Rationale for use of local hyperthermia with radiation therapy and selected anticancer drugs in locally advanced human malignancies","volume":"4","author":"Herman","year":"1988","journal-title":"Int J Hyperthermia."},{"key":"10.1016\/j.acuro.2020.08.003_bib0385","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0022-5347(01)66225-6","article-title":"Neoadjuvant combined microwave induced local hyperthermia and topical chemotherapy versus chemotherapy alone for superficial bladder cancer","volume":"155","author":"Colombo","year":"1996","journal-title":"J Urol."},{"key":"10.1016\/j.acuro.2020.08.003_bib0390","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.urology.2003.10.036","article-title":"Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer","volume":"63","author":"Gofrit","year":"2004","journal-title":"Urology."},{"key":"10.1016\/j.acuro.2020.08.003_bib0395","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0022-5347(01)67613-4","article-title":"A new approach using local combined microwave hyperthermia and chemotherapy in superficial transitional bladder carcinoma treatment","volume":"153","author":"Colombo","year":"1995","journal-title":"J Urol."},{"key":"10.1016\/j.acuro.2020.08.003_bib0400","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1200\/JCO.2003.01.089","article-title":"Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma","volume":"21","author":"Colombo","year":"2003","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.acuro.2020.08.003_bib0405","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.eururo.2004.01.019","article-title":"Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder","volume":"46","author":"van der Heijden","year":"2004","journal-title":"Eur Urol."},{"key":"10.1016\/j.acuro.2020.08.003_bib0410","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00345-009-0384-2","article-title":"Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party","volume":"27","author":"Witjes","year":"2009","journal-title":"World J Urol."},{"key":"10.1016\/j.acuro.2020.08.003_bib0415","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.juro.2009.06.017","article-title":"Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin","volume":"182","author":"Nativ","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.acuro.2020.08.003_bib0420","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3109\/02656736.2014.900194","article-title":"A clinical trial of neoadjuvant hyperthermic intravesical chemotherapy (HIVEC) for treating intermediate and high-risk non-muscle invasive bladder cancer","volume":"30","author":"Sousa","year":"2014","journal-title":"Int J Hyperthermia."},{"key":"10.1016\/j.acuro.2020.08.003_bib0425","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3109\/02656736.2016.1142618","article-title":"Recirculant hyperthermic IntraVEsical chemotherapy (HIVEC) in intermediate-high-risk non-muscle-invasive bladder cancer","volume":"32","author":"Sousa","year":"2016","journal-title":"Int J Hyperthermia."},{"key":"10.1016\/j.acuro.2020.08.003_bib0430","first-page":"426","article-title":"Analysis of tolerance and security of chemo hyperthermia with Mitomycin C for the treatment of non-muscle invasive bladder cancer","volume":"71","author":"Le\u00f3n-Mata","year":"2018","journal-title":"Arch Esp. Urol."},{"key":"10.1016\/j.acuro.2020.08.003_bib0435","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3233\/BLC-180191","article-title":"Hyperthermic Intravesical Chemotherapy for BCG Unresponsive Non-Muscle Invasive BladderCancer Patients","volume":"4","author":"De Jong","year":"2018","journal-title":"Bladder Cancer."},{"key":"10.1016\/j.acuro.2020.08.003_bib0440","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00345-015-1595-3","article-title":"Efficacy and safety of a new device for intravesical thermochemotherapy in non-grade 3 BCG recurrent NMIBC: a phase I-II study","volume":"34","author":"Soria","year":"2016","journal-title":"World J Urol."},{"key":"10.1016\/j.acuro.2020.08.003_bib0445","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00280-014-2381-4","article-title":"Intravesical thermo-chemotherapy based on conductive heat: a first pharmacokinetic study with mitomycin C in superficial transitional cell carcinoma patients","volume":"73","author":"Milla","year":"2014","journal-title":"Cancer Chemother Pharmacol."},{"key":"10.1016\/j.acuro.2020.08.003_bib0450","first-page":"875","article-title":"Electromotive delivery of mitomycin C into human bladder wall","volume":"57","author":"Di Stasi","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.acuro.2020.08.003_bib0455","first-page":"4912","article-title":"Electromotive versus passive diffusion of mitomycin C into human bladder wall: concentration-depth profiles studies","volume":"59","author":"Di Stasi","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.acuro.2020.08.003_bib0460","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/S0090-4295(97)00625-0","article-title":"Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: a comparative Phase II study","volume":"51","author":"Brausi","year":"1998","journal-title":"Urology."},{"key":"10.1016\/j.acuro.2020.08.003_bib0465","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/01.ju.0000080568.91703.18","article-title":"Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study","volume":"170","author":"Di Stasi","year":"2003","journal-title":"J Urol."},{"key":"10.1016\/j.acuro.2020.08.003_bib0470","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(05)70472-1","article-title":"Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial","volume":"7","author":"Di Stasi","year":"2006","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.acuro.2020.08.003_bib0475","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1186\/s12885-018-5134-7","article-title":"ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk \u201cBCG failure\u201d non muscle invasive bladder cancer: 3 years follow-up outcomes","volume":"18","author":"Racioppi","year":"2018","journal-title":"BMC Cancer."},{"key":"10.1016\/j.acuro.2020.08.003_bib0480","first-page":"CD011864","article-title":"Intravesical electromotive drug administration for non-muscle invasive bladder cancer","volume":"9","author":"Jung","year":"2017","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.acuro.2020.08.003_bib0485","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S0090-4295(01)01187-6","article-title":"Risk of Continued Intravesical Therapy and Delayed Cystectomy in BCG-refractory superficial bladder cancer: an investigational approach","volume":"58","author":"Luciani","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.acuro.2020.08.003_bib0490","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0090-4295(97)00067-8","article-title":"Additional bacillus Calmette-Gu\u00e9rin therapy for recurrent transitional cell carcinoma after an initial complete response","volume":"49","author":"Bui","year":"1997","journal-title":"Urology."},{"key":"10.1016\/j.acuro.2020.08.003_bib0495","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0022-5347(17)43959-0","article-title":"Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer","volume":"137","author":"Catalona","year":"1987","journal-title":"J Urol."},{"key":"10.1016\/j.acuro.2020.08.003_bib0500","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.urolonc.2005.11.026","article-title":"Final results from a national multicenter phase II trial of combination bacillus Calmette-Gu\u00e9rin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer","volume":"24","author":"Joudi","year":"2006","journal-title":"Urol Oncol."}],"container-title":["Actas Urol\u00f3gicas Espa\u00f1olas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210480620301868?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210480620301868?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T12:36:57Z","timestamp":1759322217000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0210480620301868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0210480620301868"],"URL":"https:\/\/doi.org\/10.1016\/j.acuro.2020.08.003","relation":{},"ISSN":["0210-4806"],"issn-type":[{"value":"0210-4806","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tratamientos actuales tras fracaso a BCG en c\u00e1ncer de vejiga no m\u00fasculo-invasivo","name":"articletitle","label":"Article Title"},{"value":"Actas Urol\u00f3gicas Espa\u00f1olas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acuro.2020.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 AEU. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}